Prof Maha Hussain presents data from the PROfound trial during a press conference at the 2019 ESMO congress.
This was a trial evaluating the PARP inhibitor olaparib vs new hormonal agents in patients with metastatic, pre-treated prostate cancer whose cancer cells had faulty DNA repair genes.
Watch Prof Hussain's interview with ecancer here.
Watch Dr Ignacio Duran's comment here.
Read more about the study here.